Advanced Therapies Europe 2020

29TH - 30TH SEPTEMBER 2020



Kieran Breen

Kieran Breen

Head of Research and Development, European Parkinson's Disease Association/CAT

Dr Breen has been a member of the European Medicines Agency Committee for Advanced Therapies since 2013. He is one of two experts who have been nominated by patient organizations. His areas of expertise are pre-clinical studies and the assessment of patient-reported outcomes in clinical studies. He has an academic background having initially worked at the University of Dundee (UK) and, more recently, has been involved in the strategic development of medical research programmes, both in the public and not-for-profit sectors within the UK. He is the author of over 70 peer reviewed scientific papers and regularly acts as a peer reviewer for journal manuscripts and research grant applications to a variety of funding bodies.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd